Jason Harris

The Japanese Ministry of Health, Labor, and Welfare has approved abemaciclib (Verzenio) for the treatment of patients with HR-positive, HER2-negative unresectable or recurrent breast cancer in combination with fulvestrant (Faslodex) or an aromatase inhibitor.

Abhinav Deol, MD, discusses the basics of chimeric antigen receptor T-cell therapy, potential new directions for these products, and the possible impact new products might have on the field.

Rebecca Alexandra Dent, MD, MSc, discusses which patients will derive the most benefit with ipatasertib, whether the agent can fill the unmet need for patients with PIK3CA-mutated TNBC, and what she hopes to learn from the results of the ongoing phase III IPATunity130 trial.

A new drug application has been submitted to the FDA for erdafitinib for the treatment of patients with locally advanced or metastatic urothelial carcinoma and FGFR genetic alterations whose tumors progressed following chemotherapy.

Results of the phase IIb STORM trial demonstrated that the combination of selinexor and dexamethasone demonstrated promising clinical activity in patients with penta-refractory multiple myeloma, a population that currently has no standard-of-care regimen.

Cure rates in diffuse large B-cell lymphoma remain relatively unchanged, even following therapeutic additions to the armamentarium and an improved understanding of disease biology.

Phase I data showed that combining venetoclax and navitoclax plus chemotherapy demonstrated encouraging responses and tolerability in patients with relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma.

Following survival improvements in the field of adolescents and young adults with acute lymphoblastic leukemia, researchers must turn their focus to lowering toxicity, and delivering treatment to high-risk subgroups, among others.

Safety and efficacy findings for regorafenib in patients with previously treated metastatic colorectal cancer were consistent with previous phase III results.

Bijal D. Shah, MD, discussed the challenge of treating this highly heterogeneous disease, how to choose the optimal treatment regimen, and the ongoing role of BTK inhibitors.

Andrew L. Pecora, MD, discusses the use of autologous stem cell transplantation in patients aged ≥75 years and the future of care in multiple myeloma.

Francesca Gay, MD, PhD, discusses the FORTE trial comparing carfilzomib plus lenalidomide and dexamethasone versus carfilzomib plus cyclophosphamide and dexamethasone in newly diagnosed patients with multiple myeloma.

David G. Maloney, MD, PhD, reviews the latest developments with chimeric antigen receptor T-cell therapy in patients with non-Hodgkin lymphoma.

In the setting of advanced non–small cell lung cancer, the choice of up-front immunotherapy or chemotherapy, or combinations of both, is aided by findings from several trials.

In an effort to address strategies that many patients with cancer are adopting, ASCO has endorsed recommendations regarding the use of complementary therapies to manage symptoms and adverse effects of breast cancer treatment.

Luciano J. Costa, MD, PhD, discusses the emerging potential of combing venetoclax with carfilzomib and dexamethasone as a treatment for patients with relapsed/refractory multiple myeloma.

Paul A. Bunn Jr, MD, discusses the potential for new agents to treat small cell lung cancer, the challenges involved in treating this population, and the ongoing search for biomarkers to guide treatment decisions.

Elias Jabbour, MD, discusses recent clinical trial results in acute lymphoblastic leukemia , the role of immunotherapy, and the biggest challenges facing the field.

Banu K. Arun, MD, discusses the challenge of treating patients with TNBC and BRCA1-related breast cancers, the value of genotyping, and what she hopes to see in future trial results.

A. David McCollum, MD, discusses the need for greater use of molecular profiling, the importance of tumor sidedness when selecting a treatment regimen, and the value of maintenance therapy in patients with metastatic disease.

Judith Trotman, MBChB, FRACP, FRCPA, discusses zanubrutinib’s effect on patient quality of life and how the BTK inhibitor can be used to extend survival for younger patients with WM.

The US Preventive Services Task Force issued new guidelines recommending that women aged 30 to 65 years at average risk for cervical cancer can choose to receive a Pap smear alone every 3 years or screening with the high-risk human papillomavirus test alone or cotesting every 5 years.

An expanded indication for the Paxman Scalp Cooling System to include the prevention of chemotherapy-related alopecia in patients with solid tumors will increase the population eligible for the therapy dramatically and allow for more personalized treatment options.

The guidelines for establishing HER2 status for patients with breast cancer with unclear results on initial testing have been finetuned in an update that the American Society of Clinical Oncology and the College of American Pathologists recently issued.

Sixty percent of adult survivors of pediatric CNS tumors do not achieve full functional and social independence, according to results from a study conducted by researchers at St. Jude Children’s Research Hospital and the University of Tennessee Health Science Center.

Peter Borchmann MD, sheds light on the updated JULIET data and how tisagenlecleucel fits into the paradigm of diffuse large B-cell lymphoma.

Jonathan E. Rosenberg, MD, discusses the promise of enfortumab vedotin in patients with bladder cancer who previously received a checkpoint inhibitor, and reflects on the rapid pace of change in the urothelial cancer landscape.

Noopur Raje, MD, discusses the updated results from the CRB-401 trial and next steps with bb2121 in multiple myeloma.

PF-05280014 (Trazimera), a biosimilar for trastuzumab (Herceptin), has been approved for use in the European Union to treat patients with HER2 overexpressing metastatic or early breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

The FDA has approved the Magtrace and Sentimag Magnetic Localization System used to guide lymph node biopsies in women undergoing mastectomy for breast cancer.